Neuron23 develops precision medicines targeting genetically defined neurological diseases, specifically Parkinson's and Alzheimer's, by utilizing advanced data science and human genetics to identify novel molecular targets. Their approach aims to create effective treatments that address the unmet medical needs of patients suffering from these debilitating conditions.
Funding
$213.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
SVFounders
Product
Problem
Neurological diseases like Parkinson's and Alzheimer's pose significant challenges due to their complex genetic underpinnings and the lack of targeted therapies. Traditional drug discovery methods often struggle to identify effective treatments for these genetically defined conditions, leaving a large unmet need for patients.
Solution
Neuron23 is developing precision medicines for genetically defined neurological and immunological diseases by integrating advanced data science and human genetics to identify novel molecular targets. Their approach focuses on creating targeted therapies that address the specific genetic drivers of diseases like Parkinson's and Alzheimer's. By leveraging an innovative drug discovery model, Neuron23 aims to accelerate the identification of these targets and develop effective treatments with greater efficiency. The company is currently conducting clinical trials for NEU-111, a TYK2 inhibitor for immune-mediated inflammatory disorders, and NEU-411, a kinase inhibitor for early Parkinson's disease.
Target Audience
The primary target audience includes patients suffering from genetically defined neurological diseases such as Parkinson's and Alzheimer's, as well as those with immune-mediated inflammatory disorders.
Features
- Utilizes advanced data science and human genetics to identify novel molecular targets.
- Focuses on genetically defined neurological and immunological diseases.
- Developing NEU-111, a TYK2 inhibitor with potential for immune-mediated inflammatory disorders, currently in Phase 1 clinical trials.
- Developing NEU-411, a brain-penetrant kinase inhibitor for early Parkinson’s disease, currently in Phase 2 clinical trials.
- Employs Roche's digital biomarker in Parkinson's disease clinical trial to enhance precision and reduce patient burden.